Our transcriptomic analysis reveals significantly reduced blood expression levels of the GR itself and the two GR‐induced genes, DUSP1 and TSC22D3 in relapsing GC‐resistant as compared to relapsing GC‐sensitive patients with MS (Figure 2). This evidence concerns the gene NR3C1 and myeloid sarcoma.